Sugi Predict

Sugi Predict / Compounds / SCHEMBL193326

SCHEMBL193326

SCHEMBL193326

Cc1ccc(S(=O)(=O)OP(C)(CC(C)C)(CC(C)C)CC(C)C)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.39
▸ GBA1 P04062 1/20 0.38
▸ ALDH1A1 P00352 7/20 0.38
▸ CYP3A4 P08684 2/20 0.38
▸ CYP2C9 P11712 2/20 0.38
▸ CYP2C19 P33261 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ CA2 P00918 5/20 0.37
▸ CA9 Q16790 4/20 0.37
▸ CA12 O43570 2/20 0.37
▸ VDR P11473 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ CA1 P00915 4/20 0.37
▸ CA7 P43166 2/20 0.37
▸ CA3 P07451 1/20 0.37
▸ CA6 P23280 1/20 0.37
▸ CA5A P35218 1/20 0.37
▸ CA5B Q9Y2D0 1/20 0.37
▸ CA4 P22748 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7036221 0.85 MCHR1 (0.40) GAAALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL11894229 0.85 MCHR1 (0.40) GAAALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL3417925 0.81 GAA (0.43) GAAALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL3421179 0.81 CA2 (0.39) GAAGBA1ALDH1A1CYP3A4CYP2C9
SCHEMBL11894097 0.78 TLR9 (0.41) GAAALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL306553 0.75 SMN1; SMN2 (0.41) GAAALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL11310527 0.74 GAA (0.43) GAAALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL777474 0.72 GAA (0.45) GAAGBA1ALDH1A1CYP3A4CYP2C9
SCHEMBL9777683 0.72 GAA (0.45) GAAALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL16908425 0.72 GAA (0.45) GAAALDH1A1CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 339 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11567385-B2 Electrochromic device THE BOEING COMPANY (US) 2023-01-31 — — US claimed
EP-3753973-B1 A METHOD FOR SEALING A GAP BETWEEN ADJOINING OR CONNECTED SOLID SURFACES ON AN AIRCRAFT BOEING CO (US) 2022-09-28 — — EP claimed
US-20220171247-A1 ELECTROCHROMIC DEVICE THE BOEING COMPANY 2022-06-02 — — US claimed
US-11307476-B2 Electrochromic device THE BOEING COMPANY (US) 2022-04-19 — — US claimed
US-11292853-B2 Methods and compositions for curing a surface of an uncured polysulfide rubber THE BOEING COMPANY (US) 2022-04-05 — — US claimed
US-11278222-B2 Waterless electrochemical transdermal alcohol sensor and wearable transdermal alcohol sensor device 1A SMART START LLC (US) 2022-03-22 — — US claimed
US-20210395906-A1 ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY CUSTOMARRAY INC (US) 2021-12-23 — — US claimed
EP-3753973-A1 A METHOD FOR SEALING A GAP BETWEEN ADJOINING OR CONNECTED SOLID SURFACES ON AN AIRCRAFT The Boeing Company (US) 2020-12-23 — — EP claimed
EP-3740543-A1 INCREASED SATURATION OF ICE MELTING COMPOSITIONS AND METHODS OF USE BASF SE (DE) 2020-11-25 — — EP claimed
US-20200339851-A1 INCREASED SATURATION OF ICE MELTING COMPOSITIONS AND METHODS OF USE BASF CORPORATION 2020-10-29 — — US claimed
US-20090092915-A1 PHOSPHONIUM CONTAINING CHARGE TRANSPORT LAYER PHOTOCONDUCTORS XEROX CORPORATION (US) 2009-04-09 — — US claimed
US-7482103-B2 Imaging member having antistatic anticurl back coating XEROX CORPORATION (US) 2009-01-27 — — US claimed
US-20080020311-A1 additive of ammonium salt, phosphonium salt to reduce or eliminate static charge buildup in photoreceptors and to improve image quality; electrophotographic imaging member XEROX CORPORATION (US) 2008-01-24 — — US claimed
EP-1869061-A2 ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY Combimatrix Corporation (US) 2007-12-26 — — EP claimed
US-20070215865-A1 Opto-electronic devices exhibiting enhanced efficiency GENERAL ELECTRIC COMPANY (US) 2007-09-20 — — US claimed
EP-1805206-A2 ELECTROCHEMICAL DEBLOCKING USING A HYDRAZINE DERIVATIVE Combimatrix Corporation (US) 2007-07-11 — — EP claimed
US-20070034513-A1 Electrochemical deblocking solution for electrochemical oligomer synthesis on an electrode array COMBIMATRIX CORPORATION 2007-02-15 — — US claimed
WO-2006105037-A2 ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY COMBIMATRIX CORPORATION (US) 2006-10-05 — — WO claimed
WO-2006031814-A2 ELECTROCHEMICAL DEBLOCKING USING A HYDRAZINE DERIVATIVE COMBIMATRIX CORPORATION (US) 2006-03-23 — — WO claimed
US-20060054511-A1 Electrochemical deblocking using a hydrazine derivative CUSTOMARRAY, INC. 2006-03-16 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210395906-A1 ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY DNMT1, DNASE1, DNPEP GAA 1884/4885GBA1 3182/4885ALDH1A1 2887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.